A study of effect of guggulsterone on hyperlipidemia of secondary glomerulopathy.
Hyperlipidemia in patients of secondary glomerulopathies, a well established entity with very little knowledge of its management modifies its prognosis by predisposing these patients to develop atherosclerosis, coronary artery disease, hypertension cerebro-vascular accidents and also thromboembolic phenomenon leading to renal vein thrombosis and renal failure. Guggulsterone was administered orally in these patients in a daily divided dose of 75 mg for a period of 8 weeks together with supportive measures like high protein diet, diuretics and hematinics. Total serum lipid, total serum cholesterol, triglycerides, phospholipids, HDL, LDL, and VLDL were analysed at 4 and 8 weeks of therapy. Significant reduction was observed in the values of total serum lipid and total serum cholesterol. Other parameters of lipid profile showed downward trend except rise of HDL with insignificant difference. There was no significant side effect throughout the study.
Beg
M
M
Department of Medicine, J.N. Medical College, A.M.U., Aligarh.
Singhal
K C
KC
Afzaal
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000097:blood*; D007678:Kidney Glomerulus / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011282:Pregnenediones / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D011282:Pregnenediones; C023617:pregna-4,17-diene-3,16-dione